News Bayer takes control of Loxo duo as Lilly closes takeover Bayer has acquired full rights to two drugs partnered with Loxo Oncology, on the same day that the biotech was taken over by Eli Lilly in an
News Lilly further boosts cancer pipeline with $8bn Loxo acquisit... In the second big M&A deal of the year following BMS’s acquisition
News Bayer/Loxo drug approved in cancers with certain mutation The FDA has approved Bayer and Loxo’s Vitrakvi (larotrectinib) for adults and children whose cancers have a specific genetic feature, or biomarker.
Views & Analysis ASCO 2018 - Tuesday 5th June: Tesaro developing checkpoint c... Breast cancer has been one area where checkpoint inhibitors have not yet gained traction – but that might be about to change following results announced by Tesaro at the American Society of
R&D Modelling biologics: Challenges and opportunities, with Dr D... From AAPS 2025, an interview with Dr Dhaval Shah, professor of pharmaceutical sciences at the University of Buffalo and former Pfizer researcher.
Market Access Sponsored Bridging research and clinical guidelines – interactive stra... Medical affairs is evolving. Understanding how to harness real-world data and digital insights is essential.